864494-46-2

Upstream product

• 754219-11-9 N-(3,5-dimethylphenyl)-2-thioxo-1,2-dihydropyridine-3-carboxamide 
• 864461-13-2 4-(bromomethyl)pyridin-2-amine hydrobromide 
• 105250-17-7 2-amino-4-hydroxymethylpyridine 
• 38521-46-9 3-carboxy-2-mercaptopyridine 

Relevant academic research and scientific papers

Pyridylmethylthio derivatives as VEGF inhibitors: Part 2

Optimization of compounds 5 and 6 led to the discovery of VEGF inhibitor 10g which reduced CYP inhibition. It was highly active in vitro (VEGF induced HUVEC proliferation assay) and showed efficacies in three disease models in vivo (cancer, RA, and AMD).

NOVEL CYCLIC COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP HAVING (UN)SUBSTITUTED AMINO INTRODUCED THEREIN

A novel cyclic compound having a 4-pyridylalkylthio group having an (un) substituted amino group introduced therein or a salt thereof. They are useful as a medicine. The cyclic compound is a compound represented by the following formula (1), which is useful for the treatment of diseases in which angiogenesis participates. In the following formula (1), ring A represents a benzene ring or a 5- or 6-membered aromatic heterocycle optionally fused with a cycloalkane ring; B represents alkylene; R1 and R2 each represents H, (substituted) aryl, (substituted) heterocyclic group, etc.; R3 and R4 each represents H; (substituted) alkyl, (substituted) cycloalkyl, -Z-R5, etc.; R5 represents (substituted) alkyl, (substituted) aryl, (substituted) heterocyclic group, etc.; X and Y each represents H, etc.; Z represents -CO-, -COO-, -CONR 6- -SO2-, etc.; R6 represents H, etc.; p is 0, 1, or 2; and q is 0 or 1.